Breaking News Instant updates and real-time market news.

2016-10-06 16:08:19

HELE

Helen of Troy

$86.87

0.37 (0.43%)

16:08

10/06/16

10/06

16:08

10/06/16

16:08

Helen of Troy reports Q2 adjusted EPS $1.31, consensus $1.07

Reports Q2 revenue $368.2M, consensus $368.5M. "We drove a 4.2 percentage point improvement in gross margin reflecting accretion from the Hydro Flask acquisition and our efforts to sweeten the mix and reduce our costs. We are very pleased with Hydro Flask's growth and performance, which contributed $29.1M of net sales during the quarter, fueling a 34.4% increase in net sales in our Housewares segment, and was accretive to adjusted operating margin. We saw growth and improved profitability from our Housewares and Health & Home segments, which offset significantly softer sales in our Beauty and Nutritional Supplements segments. Although Housewares experienced a slight decline in its core business in Q2, based on point-of-sale activity, we believe this segment remains on track to meet our expectations for the full year. Our Health & Home segment net sales grew 0.8%, with profitability continuing to improve from our cost savings efforts and focus on higher-margin business. Sales in our Beauty segment performed well below our expectations due to the weak retail environment and slower store traffic patterns. In addition, in an effort to build a platform for greater long-term profitability in Beauty, we made choices to rationalize lower-margin and non-strategic businesses."

06

Oct

HELEHelen of Troy

$86.87

0.37 (0.43%)

12/30/15

PIPR

12/30/15NO CHANGETarget $100PIPROverweight

Helen of Troy shares look range-bound near-term, says Piper Jaffray

Piper Jaffray analyst Stephanie Wissink believes Helen of Troy shares are likely to be range-bound in the near-term with the 2015-2016 flu season tracking below last year. Management's guidance assumes an average flu season, the analyst points out. She still sees potential share upside though 2016, however, and keeps an Overweight rating on the name.

03/07/16

JEFF

03/07/16INITIATIONTarget $114JEFFBuy

Helen of Troy initiated with a Buy at Jefferies

Jefferies analyst Trevor Young started Helen of Troy with a Buy rating and $114 price target.

03/07/16

03/07/16INITIATION

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AveXis (AVXS) initiated with a Buy at Goldman and Jefferies. Goldman analyst Salveen Richter calls the company's clinical proof-of-concept for lead gene therapy AVXS-101 in spinal muscular atrophy Type I "impressive." 2. Proteostasis (PTI) initiated with a Buy at H.C. Wainwright and an Outperform at Baird, Leerink and RBC Capital. 3. Blue bird (BLBD) initiated with a Buy at Craig-Hallum by analyst Eric Stine, who cited discounted valuation and free cash flow generation. 4. Enbridge (ENB) initiated with a Buy at Canaccord following the company's $2.3B equity financing. The firm expects the financing removes any near-term funding risks. 5. Helen of Troy (HELE) initiated with a Buy at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

08/19/16

SIDC

08/19/16UPGRADESIDCBuy

Helen of Troy upgraded to Buy from Neutral at Sidoti

Sidoti analyst Frank Camma upgraded Helen of Troy to Buy based on valuation and strong consumer brands and maintained its $112 price target.